Karadurmus N, Sahin U, Basgoz BB, Arpaci F, Demirer T. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. World J Transplant 2016; 6(4): 675-681 [PMID: 28058217 DOI: 10.5500/wjt.v6.i4.675]
Corresponding Author of This Article
Taner Demirer, MD, FACP, Professor of Medicine and Hematology/Oncology, Department of Hematology, Ankara University Medical School, Cebeci Hospital, 06220 Ankara, Turkey. demirer@medicine.ankara.edu.tr
Research Domain of This Article
Hematology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nuri Karadurmus, Bilgin Bahadir Basgoz, Department of Medical Oncology, Gulhane Military Medical Academy, Etlik, 06018 Ankara, Turkey
Ugur Sahin, Taner Demirer, Department of Hematology, Ankara University Medical School, 06220 Ankara, Turkey
Fikret Arpaci, Department of Medical Oncology, Liv Hospital, 34034 Ankara, Turkey
Author contributions: Karadurmus N, Sahin U, Basgoz BB, Arpaci F and Demirer T contributed equally to this work; Arpaci F and Demirer T designed the concept; Karadurmus N, Sahin U, Basgoz BB, Arpaci F and Demirer T wrote the paper.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Taner Demirer, MD, FACP, Professor of Medicine and Hematology/Oncology, Department of Hematology, Ankara University Medical School, Cebeci Hospital, 06220 Ankara, Turkey. demirer@medicine.ankara.edu.tr
Telephone: +90-532-3251065 Fax: +90-312-4663717
Received: July 21, 2016 Peer-review started: July 26, 2016 First decision: October 21, 2016 Revised: November 1, 2016 Accepted: November 21, 2016 Article in press: November 23, 2016 Published online: December 24, 2016 Processing time: 145 Days and 22 Hours
Core Tip
Core tip: Some refractory metastatic solid tumors including renal, ovarian and even colon cancers may respond well to allogeneic hematopoietic stem cell transplantation (allo-HSCT) with reduced intensity conditioning (RIC). Their lower toxicity profiles and lower non-relapse mortality rates constitute the advantages of RIC. The use of allo-HSCT with RIC or non-myeloablative regimens can be a feasible option among fragile patients, such as geriatric patients and patients with comorbidities. Future studies are needed for a clear-cut understanding of the mechanisms of graft-versus-leukemia and graft-versus-tumor effects of donor T-cells and their subsets in order to optimize the efficacy of such treatment modalities in patients with refractory solid tumors.
